ArticleFrontiers in oncology2026
Case Report: Three-fraction lattice radiotherapy followed by VMAT concurrent chemoradiotherapy in locally advanced non-small cell lung cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case Report: Image-guided adaptive lattice radiotherapy for a 2,772-cc ulcerative triple-negative breast cancer.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In unresectable stage III non-small cell lung cancer (NSCLC) with bulky primary tumors and extensive nodal irradiation volumes, dose escalation during concurrent chemoradiotherapy (cCRT) is often limited by the tolerance of organs at risk (OARs). Lattice radiotherapy (LRT), a form of spatially fractionated radiotherapy (SFRT), generates a characteristic intratumoral peak-valley dose distribution, which may enable focal dose intensification without increasing the dose to surrounding normal tissues. Case description: A 65-year-old man with unresectable stage IIIC (cT4N3M0) poorly differentiated squamous cell carcinoma of the right upper lobe first underwent 3 fractions of LRT. He then received volumetric modulated arc therapy (VMAT) delivered concurrently with platinum-doublet chemotherapy. During treatment, cone-beam CT (CBCT) demonstrated marked tumor regression; a second CT simulation was performed and target volumes were recontoured, reducing the primary gross tumor volume (GTVp). The patient completed the remaining 14 fractions using the new plan. Treatment was well tolerated, with only grade 1 sore throat and reversible anemia, both improving with supportive care. One month after completion, chest CT showed substantial tumor shrinkage consistent with a partial response (PR) per RECIST v1.1. Approximately 1.5 months post-treatment, radiation-induced pneumonitis occurred and improved with anti-infective/supportive management. The Eastern Cooperative Oncology Group (ECOG) performance status remained 0-1 during follow-up. Conclusions: This case suggests that, in unresectable stage III pulmonary squamous cell carcinoma, a combined strategy of limited-fraction LRT plus VMAT with concurrent chemotherapy, together with on-treatment adaptive replanning, can achieve favorable short-term efficacy and acceptable toxicity while maintaining OAR doses within constraints. This approach provides a practical reference for individualized radiotherapy with complex target volumes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.